Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (2,465) Arrow Down
Filter Results: (2,465) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (5,158)
    • People  (16)
    • News  (1,906)
    • Research  (2,465)
    • Events  (2)
    • Multimedia  (221)
  • Faculty Publications  (1,885)

Show Results For

  • All HBS Web  (5,158)
    • People  (16)
    • News  (1,906)
    • Research  (2,465)
    • Events  (2)
    • Multimedia  (221)
  • Faculty Publications  (1,885)
← Page 117 of 2,465 Results →
Sort by

Are you looking for?

→Search All HBS Web
  • August 2008 (Revised May 2009)
  • Background Note

Note on Generic Drugs in the European Union

By: Robert C. Pozen and Elizabeth M. Leonard
Rules governing the introduction of generic drugs in U.S. and EU have some similarities but significant differences because of the Hatch-Waxman Act in the U.S. View Details
Keywords: Governing Rules, Regulations, and Reforms; Government Legislation; Health Care and Treatment; Trademarks; Brands and Branding; Pharmaceutical Industry; European Union; United States
Citation
Find at Harvard
Related
Pozen, Robert C., and Elizabeth M. Leonard. "Note on Generic Drugs in the European Union." Harvard Business School Background Note 309-019, August 2008. (Revised May 2009.)
  • August 2001
  • Case

Scios, Inc.

By: Regina E. Herzlinger
Scios, filled with distinguished scientists and experienced managers, nevertheless fails to clear the FDA Phase III process for an important biotechnology drug. This case asks the students to analyze the social costs and benefits of the regulatory process. View Details
Keywords: Governing Rules, Regulations, and Reforms; Health Care and Treatment; Cost Management; Cost vs Benefits; Social Issues; Pharmaceutical Industry; United States
Citation
Educators
Related
Herzlinger, Regina E. "Scios, Inc." Harvard Business School Case 302-034, August 2001.
  • October 2021 (Revised January 2022)
  • Supplement

Michael Ku and Global Clinical Supply at Pfizer Inc.: Bringing Hope to Patients (C)

By: Linda A. Hill and Emily Tedards
This case is the third installment in a series about the 10-year cultural and digital transformation of Pfizer’s Global Clinical Supply organization. In 2011, Michael Ku became Pfizer’s Vice President of Global Clinical Supply (GCS) after the company had undergone... View Details
Keywords: Clinical Supply Chain; COVID-19; Vaccine; Agile; Innovation and Invention; Change Management; Organizational Culture; Transformation; Leadership; Corporate Strategy; Health Pandemics; Crisis Management; Mission and Purpose; Health Care and Treatment; Supply Chain Management; Digital Transformation
Citation
Purchase
Related
Hill, Linda A., and Emily Tedards. "Michael Ku and Global Clinical Supply at Pfizer Inc.: Bringing Hope to Patients (C)." Harvard Business School Supplement 422-041, October 2021. (Revised January 2022.)
  • 06 Jan 2011
  • What Do You Think?

How Should Management Deal With “Anonymous”?

it "government must be able to monitor and regulate Internet activities that adversely affect people's safety and welfare." Few were convinced that technology itself would provide more than temporary defenses. The use of the... View Details
Keywords: by James L. Heskett
  • 09 Oct 2012
  • First Look

First Look: October 9

this time. Read the article: http://hbr.org/2012/10/great-leaders-dont-need-experience/ar/1   Working PapersTeam Scaffolds: How Minimal In-Group Structures Support Fast-Paced Teaming Authors:Melissa Valentine and Amy C. Edmondson Abstract Across many industries,... View Details
Keywords: Sean Silverthorne
  • 18 Feb 2015
  • First Look

First Look: February 18

https://cb.hbsp.harvard.edu/cbmp/product/715411-PDF-ENG Harvard Business School Case 715-423 Discovery Limited Discovery Limited is a South-African based insurance company. Started in the early 1990s, Discovery used behavioral economics and data collection to innovate... View Details
Keywords: Sean Silverthorne
  • 05 Aug 2015
  • What Do You Think?

What Happened to the ‘Innovation, Disruption, Technology’ Dividend?

W. Norton & Company, 2014). Martin Ford, Rise of the Robots: Technology and the Threat of a Jobless Future (New York: Basic Books, 2015). James L. Heskett, W. Earl Sasser, Jr., and Leonard A. Schlesinger, What Great Service Leaders Know and Do: Creating... View Details
Keywords: by James Heskett; Computer; Technology
  • 09 Feb 2010
  • First Look

First Look: Feb. 9

"high-end" firm that is expected to care only for its most quality-sensitive customers can have an advantage in introducing a product relative to a firm that is expected to be more widely altruistic. Download the paper from SSRN... View Details
Keywords: Martha Lagace
  • December 2007 (Revised July 2009)
  • Case

Given Imaging Ltd. - First We Take Manhattan, Then We Take Berlin?

GI has developed a revolutionary video pill for imaging the small bowel in the gastro-intestinal tract. The development has required the integration of wide variety of technologies. GI founder and CEO Gabriel Meron must determine GI's marketing strategy and prioritize... View Details
Keywords: Medical Specialties; Globalized Markets and Industries; Decisions; Technological Innovation; Marketing Strategy; Market Entry and Exit; Entrepreneurship; Health Care and Treatment; Corporate Finance; Medical Devices and Supplies Industry; Japan; United States; Europe
Citation
Educators
Purchase
Related
Isenberg, Daniel J. "Given Imaging Ltd. - First We Take Manhattan, Then We Take Berlin?" Harvard Business School Case 808-033, December 2007. (Revised July 2009.)
  • August 2023
  • Case

Augmenix: Space to Think Differently

By: Satish Tadikonda and Sidhant Jena
Amar Sawhney, a serial medtech entrepreneur, had founded Augmenix to develop and commercialize a hydrogel-based medical device called SpaceOAR as an adjunctive technology to core radiation therapy. This technology was used to protect organs at risk (OAR) during... View Details
Keywords: Entrepreneurship; Health Care and Treatment; Technology Adoption; Innovation Strategy; Technological Innovation; Product Development; Commercialization; Medical Devices and Supplies Industry
Citation
Educators
Purchase
Related
Tadikonda, Satish, and Sidhant Jena. "Augmenix: Space to Think Differently." Harvard Business School Case 824-031, August 2023.
  • May 2018
  • Case

The Multiple Myeloma Research Foundation's Answer Fund

By: Richard G. Hamermesh and Matthew G. Preble
Keywords: Data Analytics; Customer Focus and Relationships; Customer Relationship Management; Cost vs Benefits; Investment Return; Health Care and Treatment; Innovation Leadership; Intellectual Property; Knowledge Sharing; Knowledge Dissemination; Leadership; Leading Change; Resource Allocation; Goals and Objectives; Marketing Communications; Performance; Programs; Projects; Business and Community Relations; Business and Stakeholder Relations; Networks; Partners and Partnerships; Research and Development; Genetics; Behavior; Motivation and Incentives; Social and Collaborative Networks; Nonprofit Organizations; Strategy; Health Industry; Health Industry; Health Industry; United States
Citation
Educators
Related
Hamermesh, Richard G., and Matthew G. Preble. "The Multiple Myeloma Research Foundation's Answer Fund." Harvard Business School Case 818-045, May 2018.
  • 05 Jan 2010
  • First Look

First Look: January 5

leading center for diabetes care, clinician training, and research. The incidence of diabetes is rising precipitously worldwide, challenging quality of life with its complications and rapidly accelerating health View Details
Keywords: Martha Lagace
  • 14 Oct 2002
  • Research & Ideas

The Widening Rift Between Corporations and Society

grasping the revolutionary potential of the new digital medium. As a result, corporations have failed to adapt to the true nature of their markets in the twenty-first century. Organizational change programs, visionary leadership, or increased View Details
Keywords: by Martha Lagace
  • 06 Jan 2012
  • Op-Ed

Where Green Corporate Ratings Fail

News Corporation—a multinational media conglomerate that includes BSKYB, Dow Jones, Fox News, 20th Century Fox and Star, among other units—announced earlier this year that it has become climate neutral, meaning that its operations have no net impact on global climate... View Details
Keywords: by Michael Toffel & Auden Schendler; Information; Publishing
  • 29 Jan 2008
  • First Look

First Look: January 29, 2008

executives compare the cash flows from innovation against the default scenario of doing nothing, assuming—incorrectly—that the present health of the company will persist indefinitely if the investment is not made. In most situations,... View Details
Keywords: Martha Lagace
  • 2024
  • Working Paper

Coronary Artery Bypass Grafting—Impossible to Routine: Case Histories of Transformational Advances

By: Amar Bhidé, Srikant M. Datar and Fabio Villa
We describe how Coronary Artery Bypass Grafting (CABG, or more popularly, “bypass”) operations revolutionized the treatment of coronary disease (that can produce fatal heart attacks and debilitating angina). Specifically, we chronicle the: 1) development of the... View Details
Keywords: Health Care and Treatment; Technological Innovation; Innovation Strategy; Technology Adoption; Collaborative Innovation and Invention; Innovation and Invention; Governing Rules, Regulations, and Reforms
Citation
SSRN
Read Now
Related
Bhidé, Amar, Srikant M. Datar, and Fabio Villa. "Coronary Artery Bypass Grafting—Impossible to Routine: Case Histories of Transformational Advances." Harvard Business School Working Paper, No. 20-010, July 2019. (Revised May 2024.)
  • 06 Aug 2013
  • First Look

First Look: August 6

available. Purchase this case: http://hbr.org/search/313109-PDF-ENG Harvard Business School Case 112-085 Schön Klinik: Measuring Cost and Value The case illustrates how a leading German hospital group has invested deeply in the measurement of patient-level outcomes and... View Details
Keywords: Anna Secino
  • 20 Nov 2007
  • First Look

First Look: November 20, 2007

discipline to nationalized banks. Pharmaceutical Regulation in the United States and Europe Author:Arthur Daemmrich Periodical:Focus on Law Studies 23, no 1 (fall 2007): 8-11 Read the full paper:... View Details
Keywords: Martha Lagace
  • 02 Sep 2002
  • Research & Ideas

The Role of Government When All Else Fails

they had. And this meant that economic security gradually came to rival economic growth as a major social priority. You asked about what a fourth phase might look like. Again, as a historian, I want to be careful about making open-ended... View Details
Keywords: by Laura Linard
  • 25 Sep 2018
  • First Look

New Research and Ideas, September 25, 2018

closest publicly traded peers struggling with heavy debt burdens. HCA's capital allocation choices would be crucial to its ability to provide high quality health care to patients, implement its corporate... View Details
Keywords: Dina Gerdeman
  • ←
  • 117
  • 118
  • …
  • 123
  • 124
  • →

Are you looking for?

→Search All HBS Web
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College.